Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
metabolic drugs
Biotech
Vogenx joins the IPO queue to fund phase 2-stage metabolic drug
Vogenx has joined the growing queue for the Nasdaq, as the metabolic biotech eyes an IPO to fund its SGLT1 inhibitor.
James Waldron
Jul 16, 2026 5:19am
ADA: Lilly offers deeper glimpse into triple-G obesity candidate
Jun 6, 2026 3:28pm
OrbiMed-backed Pinnacle adds $89M for oral peptides
Mar 26, 2026 10:29am
Zealand pens $2.5B cardiometabolic collab with Chinese biotech
Dec 11, 2025 5:45am
Lilly pens $1.2B pact with Sanegene to target metabolic RNA meds
Nov 10, 2025 4:05am
Barinthus enters reverse merger with metabolic disease biotech
Sep 30, 2025 10:39am
